Beyond Biotech - the podcast from Labiotech

Labiotech
  • 3.3 (3)
  • Tech News
  • Updated Weekly

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.

  1. 2d ago

    Episode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech media

    Welcome to episode 200! Today I’m delighted to welcome back a very special guest: Joachim Eeckhout, the co-founder of Labiotech, co-owner of Knowbio, and founder of The Science Marketer. Joachim tells the Labiotech story, one of vision, persistence, and a deep belief that the European life-sciences sector deserved better storytelling. We go back to the very beginning with someone who was there: the frustrations, a bike tour of France that became legendary, the leap to Berlin, the fundraising rounds, the acquisition, and the launch of this very podcast. We’ll also hear where Joachim is today with his new ventures, his candid take on the current biotech media landscape in Europe, and what he sees coming next for science communication and media in our industry. 01:30: Meet Joachim Eeckhout02:19: Early attraction to media creation04:32: Founding story of Labiotech platform06:35: Bike tour visiting biotech CEOs11:21: Identifying larger European market opportunity19:55: Raising seed funding for growth24:20: Acquisition by Inpart in 202130:48: Current work with Knowbio38:57: Future plans for Knowbio and biotech mediaInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Connecting the R&D ecosystem: 150 days into the integration of Inova, IN-PART and LabiotechWe raised our second financing round to become the largest biotech media 🚀How you can get involved in helping the industry–academia community solve global challenges

    44 min

  2. May 29

    World MS Day Special: Immunic reveals new hope for progressive MS

    Today we welcome Dr. Daniel Vitt, CEO of Immunic Therapeutics.  With World MS Day being tomorrow, the 30th of May, this is the perfect moment to focus on multiple sclerosis — a disease that affects nearly three million people worldwide and still leaves many patients searching for better options. In today’s episode Daniel shares his own journey into biotechnology, walk us through what life with MS really looks like for patients, and explain the science behind Immunic’s most advanced program, IMU-838. We discuss what makes Immunic’s oral therapy different from today’s treatments, uncover the latest data from the CALLIPER and ENSURE trials, and talk about what the future of MS care could look like. 01:22 Meet Daniel Vitt04:54 Understanding multiple sclerosis07:53 Evolution of the MS treatment landscape12:08 Immunic’s lead MS therapy explained22:57 World MS Day and what's next for ImmunicInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  11 neuroscience biotech companies you should know aboutThe emergence of BTK inhibitors in multiple sclerosis treatment: Companies close in on approvalSix biotech companies advancing multiple sclerosis therapies

    28 min

  3. May 22

    The problem at the heart of drug discovery: Lexogen & Ochre Bio on the power of AI on human data

    Today I am welcoming two guests: Quin Wills, CEO of Ochre Bio, a biotech developing RNA therapies for chronic liver disease using AI models, and Stéphane Barges, CEO of Lexogen, an RNA transcriptomics company and NGS service provider. It’s a deep dive into cutting edge transcriptomics, human-first data, and artificial intelligence. 00:55: The challenges of liver disease 04:44: How Lexogen supports NGS drug discovery 07:29: Major transcriptomics developments 10:05: Designing high quality AI data 15:47: How the Ochre-Lexogen partnership began 17:17: Why a specialist partner is essential for scale 18:21: Lexogen delivers on the massive sequencing project 21:50: Why high quality data is crucial 27:02: Lexogen's role in AI discovery 34:51: Future plans and directions This episode was produced with the support of Lexogen. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Deep phenotyping brings accuracy to precision medicineSpatial Transcriptomics: A window into diseaseSpatial Transcriptomics Landscape Shifts With Two Major Acquisitions

    39 min

  4. May 15

    Freeze variability, not progress: strengthen your cell therapy supply chain from the start

    Today, we're digging into a topic that's getting a lot more attention lately, how early decisions in cell therapy end up shaping or complicating everything that comes later. Our episode today is Freeze Variability, Not Progress, How to Strengthen Your Cell Therapy Supply Chain from the Start, and we're going to challenge a few long-held beliefs about how starting material should be handled.  My guest today is Dominic Clarke, Vice President of Technical Operations for IntegriCell at Cryoport Systems. Dominic has spent years in the trenches building and scaling cell therapy processes from early development through commercialization. So, he's seen where things break and what actually works. I hope you enjoy my conversation with Dominic Clark. 01:07    Meet Dominic Clarke and Cryoport Systems06:24   Fresh cells versus frozen cells08:21    Why teams switch to cryopreservation late12:37    The challenge of variability16:47    IntegriCell when you already have a process in place22:17    An argument for cryopreservation based on data25:56   The future of IntegriCell and Cryoport SystemsThis episode is brought to you with the support of Cryoport Systems. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  IntegriCell® CryopreservationCryoport Systems on the state of the ATMP market and the importance of supply chain resilienceCracking the code: Delivering biotherapeutics successfully across EMEA

    30 min

  5. May 7

    Making labs smarter for scientific breakthroughs

    Today, we dive into the future of lab management with Ryan Cawood, CEO and co-founder of Lab Thread. Ryan's journey spans groundbreaking work in virotherapy and gene delivery during his D.Phil at Oxford, to founding OXGENE, a cell and gene therapy innovator acquired by WuXi Advanced Therapies in 2021. We'll explore the frustrations of fragmented lab tools that inspired Lab Thread's integrated digital solution—combining ELN, LIMS, molecular biology, and collaboration in one seamless platform. We’ll uncover how it boosts reproducibility, ensures compliance, and frees scientists for innovation, with accessible pricing for academics and biotechs. I hope you enjoy Ryan’s insights on evolving digital workflows and accelerating breakthroughs in the lab. 01:51: Meet Ryan Cawood 02:31: Frustrations with early digital tools. 03:19: Daily lab organization challenges. 06:50: Time lost to admin tasks. 11:09: Genesis of the Lab Thread concept. 13:53: Integrated workflow functionality explained. 17:23: Enhancing experiment reproducibility methods. 20:37: Achieving compliance standards easily. 26:10: The future of digital lab management. 28:33: Accelerating scientific breakthroughs. This episode is brought to you with the support of Lab Thread. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Lab Thread - Your Lab, ConnectedHiding in plain sight: how to solve bioscience’s software problemLab chaos and digital dreams

    31 min

  6. Apr 30

    How Epicrispr is leveraging CRISPR without cutting DNA

    This week we dive into the Beyond Biotech archive to bring you a discussion with Dr Stanley Qi, the founder of Epicrispr. Epicrispr is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector.  In this episode we discuss epigenetic editing, why it’s reversible, and how it can treat FSHD and other conditions.  01:43 Meet Stanley Qi03:32 Founding Epicrispr05:53 CRISPR interference and epigenome explained10:04 Overview of GEMS gene modulation system11:28 Reversibility and safety of epigenetic edits18:42 Strategy for tackling multiple disease conditions23:27 Clinical trial plans for EPI-321 candidate30:06 Looking forwardThis episode is brought to you with the support of MedChemExpress. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Could CRISPR really cure these diseases?10 gene therapy companies you should know aboutCRISPR technology’s next wave: Ten companies to watch

    33 min

  7. Apr 24

    Diagonal Therapeutics’ innovative clustering antibodies for vascular diseases

    Today we’re joined by Patrick Andre, Chief Scientific Officer at Diagonal Therapeutics. A trained vascular biologist, Patrick’s career spans groundbreaking work at Pfizer, Acceleron, Pliant Therapeutics, and earlier companies, where he focused on TGF-β superfamily signaling and receptor pathways that keep blood vessels healthy. Now at Diagonal, he’s leading a bold mission: developing clustering antibodies that correct the root cause of serious genetic vasculopathies, rather than just managing symptoms. In this episode, Patrick walks us through his personal journey into science, the company’s DIAGONAL platform, and their lead program DIAG723, which recently received Orphan Drug Designation for the rare disease HHT, and is advancing toward the clinic. We also discuss Diagonal’s oversubscribed $125 million Series B financing that closed in January 2026, and what clustering antibodies could mean for patients with HHT, pulmonary arterial hypertension, and beyond. 01:33 Meet Patrick Andre08:01 Diagonal’s mission11:39 What are clustering antibodies16:05 Receptor clustering benefits for HHT and PAH20:24 Preclinical data on preventing and reversing HHT pathology22:39 The impact of the $125 Million Series B financing roundInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Vaderis emerges from stealth to start HHT trialPulmonary hypertension after Winrevair: where GSK’s $950M bet fitsNew treatment for pulmonary hypertension: what biotech holds in store?

    31 min

  8. Apr 17

    Argobio: the venture model building Europe’s next biotech champions

    Our guest today is Thierry Laugel, Managing Partner of Kurma & Chairman of Argobio. With a PharmD, PhD in pharmacology, and an INSEAD MBA, Thierry has spent more than two decades bridging cutting-edge science and commercial success—first in pharma R&D, then as co-founder of Kurma Partners, and now leading Argobio’s unique venture-builder model. Since raising €50 million in 2021, Argobio has co-founded and accelerated several companies from top European academic labs. Three of them—Enodia, Laigo Bio, and Elkedonia—have already closed seed rounds totaling more than €43 million, advancing novel platforms in targeted protein degradation, precision membrane protein degraders, and non-hallucinogenic neuroplasticity enhancers for depression.  Thierry shares how Argobio reduces execution risk, embeds operational expertise, and turns promising science into investable companies that can compete worldwide.  04:02 Blending pharmacology expertise with business07:50 Vision behind starting Kurma Partners12:53 Launching Argobio to address gaps in European biotech 17:40 What makes the Argobio operational venture builder model unique25:02 Criteria for selecting academic scientific breakthroughs27:34 Changing dynamics of commercializing European research35:30 Europe vs US biotech investment climates37:47 Role of venture studios in Europe’s biotech futureInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  M Ventures: pharma CVC and biotech innovation in 2026Inside Flagship Pioneering's strategy: How this VC turns ideas into biotech giantsVenture capital co-creation: The next big thing in biotech investment?

    42 min
See All (200)

Ratings & Reviews

3.3
out of 5
3 Ratings

About

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.

Information

You Might Also Like